| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39593 | COLLEGIUM PHARM INC | 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects |
Aug, 2022
(1 year, 8 months ago) | |
| US7994364 | COLLEGIUM PHARM INC | Crystalline forms of (−)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride |
Jun, 2025
(1 year, 2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6071970 | COLLEGIUM PHARM INC | Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases |
Jun, 2017
(6 years ago) | |
| US11007156 | COLLEGIUM PHARM INC | Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol |
Oct, 2022
(1 year, 6 months ago) | |
| US8309060 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8075872 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8420056 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Nov, 2023
(5 months ago) | |
| US8114383 | COLLEGIUM PHARM INC | Abuse-proofed dosage form |
Oct, 2024
(5 months from now) | |
| US11344512 | COLLEGIUM PHARM INC | Titration of tapentadol |
Apr, 2028
(3 years from now) | |
| US8536130 | COLLEGIUM PHARM INC | Use of 1 phenyl-3-dimethylamino-propane compounds for treating neuropathic pain |
Sep, 2028
(4 years from now) | |
Nucynta Er is owned by Collegium Pharm Inc.
Nucynta Er contains Tapentadol Hydrochloride.
Nucynta Er has a total of 10 drug patents out of which 6 drug patents have expired.
Expired drug patents of Nucynta Er are:
- US6071970
- US11007156
- US8309060
- US8075872
- US8420056
- USRE39593
Nucynta Er was authorised for market use on 25 August, 2011.
Nucynta Er is available in tablet, extended release;oral dosage forms.
Nucynta Er can be used as a method of titrating an opioid to manage pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate, management of neuropathic pain associated with diabetic peripheral neuropathy, relief of moderate to severe chronic pain.
Drug patent challenges can be filed against Nucynta Er from 20 November, 2012.
The generics of Nucynta Er are possible to be released after 22 September, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Aug 25, 2014 |
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2013 |
| New Indication(I-656) | Aug 28, 2015 |
Drugs and Companies using TAPENTADOL HYDROCHLORIDE ingredient
NCE-1 date: 20 November, 2012
Market Authorisation Date: 25 August, 2011
Treatment: Relief of moderate to severe chronic pain; Management of neuropathic pain associated with diabetic peripheral neuropathy; A method of titrating an opioid to manage pain severe enough to require daily,...
Dosage: TABLET, EXTENDED RELEASE;ORAL
NUCYNTA ER family patents
